The company states: “On April 21, after a decades-long career, Melissa Baird, Chief Operating Officer of Hims & Hers Health, announced her intention to transition into an advisory role with Hims & Hers in the coming months. The effective date of Ms. Baird’s departure has not yet been determined. To assure a smooth transition, she intends to remain with the Company until her successor has been identified, is in place, and fully up to speed on the business. Ms. Baird and the Company will enter into a long-term agreement at the time of her transition so the Company can continue to benefit from her specialized expertise.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Sell Rating for Hims & Hers Health Due to Slowing Sales Growth and Regulatory Risks
- Hims & Hers price target raised to $25 from $21 at Jefferies
- Hims & Hers price target lowered to $33 from $39 at Truist
- ‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
- ‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)